I

    Immutep Ltd ADR (IMMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.37
    -0.01 (-3.94%)

    Market Cap: $56.15M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(8/12)
    Avg Surprise
    +40.40%
    PeriodReportedEst.SurpriseB/MYoY
    Dec 25
    		$-0.22$-0.20-9.90%Miss-984.0%
    Sep 25
    		$0.00$0.00N/ABeat-
    Jun 25
    		$-0.03N/A+80.20%Beat+83.0%
    Mar 25
    		$0.00$0.00N/ABeat-
    Dec 24
    		$-0.02N/A+85.71%Beat+88.9%
    Sep 24
    		$0.00$0.00N/ABeat-
    Jun 24
    		$-0.18$-0.13-33.16%Miss-19.2%
    Mar 24
    		$0.00$0.00N/ABeat-
    Dec 23
    		$-0.18$-0.13-40.73%Miss-16.6%
    Sep 23
    		$0.00$0.00N/ABeat-
    Jun 23
    		$-0.15$-0.16+7.38%Beat-
    Mar 23
    		$0.00$0.00N/ABeat-
    Dec 22
    		$-0.15$-0.16+3.26%Beat-
    Sep 22
    		$0.00$0.00N/ABeat-
    Jun 22
    		$0.00N/A+100.00%Beat-
    Mar 22
    		$0.00$0.00N/ABeat+100.0%
    Dec 21
    		$0.00N/A+100.00%Beat+100.0%
    Sep 21
    		$0.00$0.00N/ABeat+100.0%
    Jun 21
    		$0.00N/A+100.00%Beat+100.0%
    Mar 21
    		$-0.01$0.00N/AMiss+8.2%
    Dec 20
    		$-0.38$-0.36-5.56%Miss-6809.1%
    Sep 20
    		$-0.01$0.00N/AMiss-184.6%
    Jun 20
    		$-0.01$0.00N/AMiss-174.0%
    Mar 20
    		$-0.01$0.00N/AMiss+35.1%
    Dec 19
    		$-0.01$0.00N/AMiss+42.1%
    Sep 19
    		$-0.01$0.00N/AMiss+47.5%
    Jun 19
    		$-0.01$0.00N/AMiss+51.0%
    Mar 19
    		$-0.01$0.00N/AMiss+19.7%
    Dec 18
    		$-0.01$0.00N/AMiss+21.5%
    Sep 18
    		$-0.01$0.00N/AMiss-50.0%
    Jun 18
    		$-0.01$0.00N/AMiss-52.2%
    Mar 18
    		$-0.01$0.00N/AMiss+86.0%
    Dec 17
    		$-0.01$0.00N/AMiss-44.0%
    Sep 17
    		$-0.01$0.00N/AMiss+4.3%
    Jun 17
    		$-0.01$0.00N/AMiss-
    Mar 17
    		$-0.08$0.00N/AMiss-
    Dec 16
    		$-0.01N/A+97.67%Beat-
    Sep 16
    		$-0.01$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.48EV/EBITDA-2.94x
    Price/FCF-1.32xFCF Yield-75.96%
    Profitability
    Profit Margin0.00%Operating Margin-764.00%
    ROE-61.90%ROIC-66.99%
    Financial Health
    Debt/Equity0.00xInterest Coverage-2684.22x
    Current Ratio2.97xQuick Ratio2.97x
    Trading Statistics
    Beta2.19Avg Volume123.55K
    52-Week High$3.3252-Week Low$0.29

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.38
    SMA 20$0.39
    SMA 50$0.40
    SMA 200$1.31
    EMA 10$0.38
    EMA 20$0.39
    EMA 50$0.42
    EMA 200$0.99

    MACD

    Line: -0.01Signal: -0.00Hist: -0.00

    ADX

    ADX: 10.5+DI: 12.1-DI: 20.1

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down100.0
    PSAR$0.40

    Bollinger Bands

    Upper Band$0.40
    Lower Band$0.37
    %B Position868%(Upper)
    Band Width-0.10

    RSI (14-Day)

    Neutral
    38.0

    Momentum Oscillators

    Stoch %K22.2
    Stoch %D25.0
    Williams %R-88.0
    ROC (10d)-5.3%
    Momentum-0.02
    CCI (20d)-306.1
    MFI (14d)36.3

    Volatility Measures

    ATR (14d)$0.02(5.6%)
    StdDev (20d)0.01
    Hist Vol43.7%(High)

    Volume Flow

    VWAP$0.37
    OBV746.9M
    AD Line-727.0M
    CMF (20d)-0.126

    Volume Metrics

    Avg Vol (20d)122.5K
    Vol Ratio1.4x
    VWMA (20d)$0.39

    Pivot Points

    R3$0.40
    R2$0.40
    R1$0.39
    Pivot Point$0.38
    S1$0.38
    S2$0.37
    S3$0.37

    Advanced Oscillators

    TSI-10.18
    Ultimate Osc35.1
    KST-40.00

    Financial Data

    QuarterDec 2025Jun 2025Dec 2024Sep 2024Jun 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022
    Total Revenue$6.03M$1.90M$3.15M$1.73M$1.73M$2.11M$1.82MN/AN/A$1.69M$170,369N/A
    Cost of Revenue$46.62M$36.08M$25.33M$21.11M$21.11M$995,788$924,019N/AN/A$935,195$1.12MN/A
    Gross Profit$-40,596,078$-34,183,766$-22,182,993$-19,379,132$-19,379,132$1.11M$896,169N/AN/A$750,339$-946,330N/A
    Operating Expenses$5.43M$40.49M$29.56M$25.16M$25.16M$25.24M$20.91MN/AN/A$22.17M$18.51MN/A
    R&D$0$36.08M$25.33M$21.11M$21.11M$20.44M$9.82M$0$0$18.97M$10.71M$0
    SG&A$5.43M$4.41M$4.23M$4.05M$4.05M$4.80M$4.55M$0$0$4.13M$2.91M$0
    Operating Income$-46,025,634$-74,674,496$-51,747,299$-44,539,830$-44,539,830$-43,564,356$-21,830,440N/AN/A$-23,106,590$-19,455,580N/A
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$18,940$12,560$11,421$19,808$19,808$10,786$5,414$0$0$14,987$4,074$0
    Income Before Tax$-44,859,721$-39,056,736$-22,377,429$-21,488,434$-21,488,434$-21,228,191$-19,273,098$0$0$-20,623,250$-15,940,613$0
    Income Tax Expense$0$0$0$21.11M$21.11M$2$1$0$0$-5$-18$0
    Net Income$-44,859,721$-39,056,736$-22,377,429$-21,488,434$-21,488,434$-21,228,191$-19,273,098N/AN/A$-20,623,250$-15,940,613N/A
    EBITDA$-44,897,114$-36,483,690$-26,393,158$-22,346,077$-22,346,077$-22,198,291$-19,070,567N/AN/A$-20,501,524$-18,338,880N/A
    EBIT$-46,025,634$-38,594,627$-26,416,635$-23,429,564$-23,429,564$-23,194,079$-19,994,586$-10,005,127$-10,005,127$-21,436,719$-19,455,579$-8,497,071
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMMP

    News

    Immutep Limited Unveils August 2026 Corporate Presentation Highlighting Pipeline Progress and Financial Health

    Immutep Limited has released its August 2026 corporate presentation, detailing a cash balance of A$68.87 million as of June 30, 2026, which provides a financial runway into the first half of 2028. The company announced the discontinuation of its Phase III TACTI-004 trial, the termination of a licensing agreement with Novartis, and a new licensing deal with Dr. Reddy's for efti, alongside ongoing cost-reduction efforts. Immutep's pipeline includes four clinical-stage assets for cancer and autoimmune diseases, supported by a strong intellectual property portfolio.

    Kalkine Media•8/20/26•
    Neutral

    Immutep Releases August 2026 Corporate Presentation Outlining Pipeline and Financial Position

    Immutep Limited (ASX:IMM, NASDAQ:IMMP) has released its August 2026 corporate presentation, detailing a cash position of A$68.87 million as of June 30, 2026, with a projected runway into the first half of 2028. The company provided updates on its clinical pipeline, including the discontinuation of its Phase III TACTI-004 trial and the termination of a licensing agreement with Novartis, while highlighting a new licensing deal with Dr. Reddy's that could bring significant milestone payments and royalties. Cost-reduction measures are underway to extend its financial runway.

    Kalkine•8/19/26•
    Neutral

    Short Interest in Prima BioMed Ltd (NASDAQ:IMMP) Declines By 44.4%

    Short interest in Prima BioMed Ltd (NASDAQ:IMMP) significantly dropped by 44.4% in July, totaling 1,195,547 shares as of July 31st. This represents 0.8% of outstanding shares and a 5.4-day-to-cover ratio. While institutional ownership remains low at 2.32%, analyst sentiment is mixed, with a consensus "Hold" rating and a $5.50 target price, despite the stock trading near its 52-week low.

    MarketBeat•8/17/26•
    Neutral

    Immutep Ltd (IMMP) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Immutep Ltd (IMMP), detailing analyst ratings and price targets. Based on two analysts, the stock has a "Buy" rating with an average target price of $8.26, indicating a significant upside potential of over 1300%. The article also notes the company's current stock performance and market capitalization.

    TradingKey•8/13/26•
    Bullish

    Immutep Ltd (IMMP) Stock News Today

    This article provides a brief update on Immutep Ltd (IMMP) stock news. It states that more news will be coming soon regarding the company's earnings, analyst ratings, and key developments. The page also displays current stock information for IMMP, including its price, daily change, and market cap.

    TradingKey•8/8/26•
    Neutral

    Frequently Asked Questions About IMMP

    Does IMMP pay dividends?
    Immutep Ltd ADR (IMMP) does not currently pay a regular dividend.
    What is IMMP's market cap?
    Immutep Ltd ADR (IMMP) has a market capitalization of $56.15M with a current stock price of $0.37.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In